CCM
TVTX icon

Cinctive Capital Management’s Travere Therapeutics TVTX Stock Holding History

Cinctive Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$415K Buy
13,966
+3,117
+29% +$93.2K 0.03% 311
2025
Q4 		$415K Sell
10,849
-83,807
-89% -$2.73M 0.02% 339
2025
Q3 		$2.26M Buy
+94,656
New +$1.78M 0.11% 240

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cinctive Capital Management's TVTX Position: Q1 2026 in Review

Cinctive Capital Management increased its Travere Therapeutics (TVTX) stake by 29% in Q1 2026, buying an estimated $93.2K and bringing the position to 13,966 shares worth $415K. The position accounts for 0.03% of the portfolio, ranked #311.

Cinctive Capital Management first reported a position in TVTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.26M in Q3 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Cinctive Capital Management held 13,966 shares of Travere Therapeutics worth $415K as of Q1 2026.
  • Cinctive Capital Management bought 3,117 Travere Therapeutics shares in Q1 2026, an estimated $93.2K.
  • Travere Therapeutics made up 0.03% of Cinctive Capital Management's portfolio in Q1 2026, its #311 holding.
  • Cinctive Capital Management first reported a position in Travere Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Cinctive Capital Management's Travere Therapeutics position peaked at $2.26M in Q3 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Cinctive Capital Management's 13F filing for Q1 2026, filed 15 May 2026.